Truscreen Group (NZSE:TRU) ROCE % : -95.93% (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Truscreen Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Truscreen Group's annualized ROCE % for the quarter that ended in Sep. 2024 was -95.93%.

Truscreen Group ROCE % Historical Data

The historical data trend for Truscreen Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Truscreen Group ROCE % Chart

Truscreen Group Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

-54.93

-37.08

-119.94

-97.74

-87.23

Truscreen Group Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
ROCE %	Get a 7-Day Free Trial															-111.18	-108.62	-160.84	-89.96	-95.93

Truscreen Group ROCE % Calculation

Truscreen Group's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	-2.548	/	( ( (3.47 - 0.889)	+	(4.03 - 0.769) )	/ 2 )
	=	-2.548	/	( (2.581	+	3.261)	/ 2 )
	=	-2.548	/	2.921
	=	-87.23 %

Truscreen Group's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	-2.69	/	( ( (4.03 - 0.769)	+	(3.525 - 1.178) )	/ 2 )
	=	-2.69	/	( ( 3.261	+	2.347 )	/ 2 )
	=	-2.69	/	2.804
	=	-95.93 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2024) EBIT data.

Truscreen Group (NZSE:TRU) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Truscreen Group ROCE % Related Terms

Thank you for viewing the detailed overview of Truscreen Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Truscreen Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Truscreen Group Ltd (NZSE:TRU) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TRU:Australia

Address

C/- HLB Mann Judd Limited, 57 Symonds Street, Level 6, Equitable House, Grafton, Auckland, NZL, 1010

Website

https://www.truscreen.com

Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening system which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.